Technical Articles

Acute myeloid leukemia is a highly heterogeneous group of hematologic malignancies, and its prognosis assessment involves multiple factors. Traditionally, age, history of hematologic disorders, karyotype, and gene mutation profiles have been important bases for evaluating patient prognosis, and these factors collectively determine the selection of treatment strategies.

The refractoriness and high relapse rate of acute myeloid leukemia are largely attributed to a population of leukemia stem cells with self-renewal capacity.